**EFA PATIENTS’ DIGITAL PRIZE 2023**

**Submission Form**

The **EFA Patients’ Digital Prize** is granted by the European Federation of Allergies and Airways Diseases Patients’ Associations (EFA). It will acknowledge digital technologies that fit in one of three disease-focused categories:

* Prize for best digital technology covering asthma.
* Prize for best digital technology covering COPD.
* Prize for best digital technology covering both asthma & COPD.

More information about EFA and the Prize can be found in this website: <https://efanet.org/inform/patient-evidence/dig-it/prize>

**Applicant’s information**

|  |  |
| --- | --- |
| First name |  |
| Last name |  |
| Company name (if applicable) |  |
| Role |  |
| e-mail address |  |
| Phone (landline) |  |
| Mobile Phone |  |
| Acknowledgement and acceptance of the ***EFA Digital Patients Prize*** *terms of reference for participants* |  |
| Acknowledgment that by participating in the ***EFA Digital Patients’ Prize***, your personal information will be processed in accordance of EFA [Privacy policy](https://efanet.org/privacy-policy) |  |

**Submission Form**

|  |  |  |
| --- | --- | --- |
| 1. Name of the digital solution (commercial name and acronym) | |  |
| 2. Links to information, technical specifications and if available the download the digital solution. If sending this information as attachments, please number them and title them to be taken into account. | |  |
| 3. Countries where the digital solution is currently used | |  |
| 4. Languages in which the digital solution is available | |  |
| 5. Cost of one unit of the digital solution, if applicable. If the solution is free of charge but has premium features, please specify. | |  |
| 6. Is the digital solution eligible for reimbursement according to the local reimbursement scheme (if available)? | | * Yes * NO * NA |
| 7. What’s the equipment patients need to be able to use the digital solution (e.g. electricity, internet connection, computer, smartphone) | | |
|  | | |
| 8. Please, describe the main target audience of the digital solution (e.g. patients, carers, healthcare professionals, health-centers, payers) | | |
|  | | |
| 9. Please, share the description used to promote your digital solution and describe its aim and if it is linked to any specific device. | | |
|  | | |
| 10. On which disease area(s) does your digital solution focus? | | * Asthma * COPD * Both diseases |
| 11. Have patients collaborated in the digital solution development? | | * Yes * No |
| 11.a If yes, please explain how patients were involved during the development (e.g. co-creation exercise, focus group, clinical trial, survey, etc) | | |
|  | | |
| 12. Does the digital solution connect patients with/to other relevant stakeholders? | | * Yes * No |
| 12.a If yes, to who,? (several options possible) | | * National/local health system / authority   Healthcare professionals (e.g. General Practitioners, Physicians, Nurses, etc.)   * Specialised doctors * Social services * Education experts * Private company owning the digital solution * Others:……………………………………... |
| 12.b What is the role of the stakeholders? Please describe it for each of the stakeholders chosen | | |
|  | | |
| 13. Does the digital solution target specifically one of these topics that can foster equity in healthcare? | | * Help patients to access to best quality of care * Reduce inequalities in access to care across borders, urban/rural setting, and healthcare providers * Foster digital mobility and transferability across European borders * Any other topic concerning equity in access to healthcare. Please, describe it briefly (max 40 words):…………………………………………………………………………………………... * No, the solution has no focus on equity in access to healthcare. |
| 14. Does the digital solution have a specific feature that helps in preventing exacerbation of the disease (whether asthma or COPD)? | | * Yes * No |
| 14.a If yes, please describe it briefly (max 100 words). | | |
|  | | |
| 15. How does this digital solution stand out increasing patient’s quality of care (e.g. provide faster and safer access to diagnosis; minimise the burden of use; etc.)? | | |
|  | | |
| 16. Please reply to the following questions regarding digital support and data safety: | | |
| 16.a Does the digital solution provide a clear, lay explanation of its objectives, functioning, and expected results? | | |
|  | | |
| 16.b Patients using your app: | * Are in control of their own data * Can easily access their health data * Can easily transfer their health data * Can easily review their health data * Can easily revoke their health data | |
| 16.c Can the stakeholders (as identified in question 12a) access the patients’ health data provided through the app? If so, for what purposes? | | |
|  | | |
| 16.d Does the digital solution require consent from patients to share health data with other stakeholders? | | |
|  | | |
| 16.e Are the terms of use of the data sharing easy to understand? (Please upload a copy of the terms of use of the digital solution submitted) | | |
|  | | |

**Thank you for filling in this document. Please submit your application and the attachments you might have, by sending an email by 27/03/2023 to:**

[projects@efanet.org](mailto:projects@efanet.org)

European Federation of Allergy and Airways Diseases Patients Associations (EFA)

35 Rue du Congrès, 1000 Brussels, Belgium

+32(0)2 227 27 12